Cisplatin-Induced Bradycardia: A Silent Risk Observed in Two Different Clinical Cases

Cureus. 2021 Nov 20;13(11):e19769. doi: 10.7759/cureus.19769. eCollection 2021 Nov.

Abstract

Cisplatin is a platinum-containing drug that inhibits DNA synthesis by inhibiting cross-linking, denaturing DNA strands. It is used in combination with other chemotherapeutic agents to treat several types of cancers. Numerous adverse effects have been reported with this compound. However, it is considered a safe medication in terms of cardiotoxicity. In this report, we discuss the case of two patients who experienced bradycardia while receiving cisplatin as part of combination therapy. A workup was undertaken to rule out other possible causes of bradycardia, and the diagnosis of cisplatin-induced bradycardia was made.

Keywords: bradycardia; cardiotoxicity; cisplatin; cisplatin-induced cardiotoxicity; germ cell tumour.

Publication types

  • Case Reports